Continuum Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Continuum Advisory's XBI Position: Q1 2026 in Review
Continuum Advisory reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.8% in Q1 2026, selling an estimated $18.2K and leaving 3,683 shares worth $470K. The position accounts for 0.05% of the portfolio, ranked #291.
Continuum Advisory first reported a position in XBI in Q1 2024 and has held it in 8 quarters since. The position peaked at $3.2M in Q3 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Continuum Advisory held 3,683 shares of State Street SPDR S&P Biotech ETF worth $470K as of Q1 2026.
- Continuum Advisory sold 146 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $18.2K.
- State Street SPDR S&P Biotech ETF made up 0.05% of Continuum Advisory's portfolio in Q1 2026, its #291 holding.
- Continuum Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and has held it in 8 quarters since.
- Continuum Advisory's State Street SPDR S&P Biotech ETF position peaked at $3.2M in Q3 2024.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.